Ilyang Pharmaceutical일양약품

Ilyang Pharmaceutical is loss-making on an operating basis over the last twelve months and its shares have fallen sharply, while regulators have named it an unfaithful disclosure company.

Over the trailing twelve months to H1 2026 the company reported revenue of ₩278B but an operating loss of ₩13.7B, with net income of ₩17.3B still positive. The share price is ₩6,960, down 46.7% over one year, and the 52-week low is shown as zero in the data, so the trading range is unclear. Filings in early October 2026 include designations as an unfaithful disclosure company, and a sales or supply contract was terminated in September.

What stands out

• Operating income was negative over the trailing twelve months, at -4.9% margin, after a ₩5.0B operating profit in 2025 and ₩11.0B in 2024.
• Net income of ₩17.3B is well above operating income, so the profit figure likely depends on non-operating items; the data does not break this down.
• Free cash flow was ₩28.3B and cash was ₩12.9B against borrowings of ₩103.1B, with liabilities at 75.8% of equity.
• The stock trades at a trailing P/E of 7.7 and P/B of 0.5, with a 2.2% dividend yield, well below the listed peers shown.
• Foreign ownership fell from 6.2% to 5.2% over about 60 days, and the 20-day flows show foreign selling against retail buying.
• The data includes a fair value model giving a base of ₩2,310, a bear of ₩0 and a bull of ₩14,628; these are model outputs, not forecasts or targets.

What to watch

• The outcome of the unfaithful disclosure designation and any follow-up filings from the company or the exchange.
• Whether the operating loss continues in the next reported period, given the terminated sales or supply contract.
• Upcoming results and any changes to borrowings, which are large relative to cash.